progression free survival for PET-positive patients was 67%, a rate similar to that for PETnegative patients treated with R-CHOP-14 (74%, P=0.11); overall survival was 78% and 88% (P=0.11), respectively. In an exploratory analysis, progression free and overall survival were markedly superior for PET-positive Deauville score 4 versus score 5 (P=0.0002 and P=0.001). Hence, diffuse large B-cell lymphoma patients who are PETpositive after 4 cycles of R-CHOP-14 and switched to R-ICE and 90 Y-ibritumomab tiuxetan-BEAM achieve favourable survival outcomes similar to that for PET-negative R-CHOP-14-treated patients. Further studies are warranted to confirm these promising results.
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INTRODUCTION
In the treatment of diffuse large B-cell lymphoma (DLBCL), combination immunochemotherapy with R-CHOP given for 6-8 cycles at intervals of 14-21 days is considered standard of care in most parts of the world [1] [2] [3] . Despite the clear benefit for the addition of rituximab to CHOP chemotherapy, still nearly 40% of patients have disease which will either fail to respond or manifest early relapse [1] [2] [3] . Furthermore, patients with high risk
International Prognostic Index (IPI) have a 5-year progression-free survival (PFS) of only 40% following R-CHOP 4 . Therefore, more intensive treatment protocols, such as high dose therapy (HDT) and autologous stem cell transplantation (ASCT), have been advocated 5, 6 . These, however, are associated with considerable increased cost and toxicity 5, 6 . One of the largest randomised trials incorporating ASCT conducted without PET scans failed to
show an obvious benefit of early dose-escalated sequential HDT 7 . Similar trials used a variety of study designs, and the value of treatment intensification remains unresolved;
suffice to say that such treatment is feasible, but at the price of greater toxicity than that associated with the current standard treatment. A more individualized approach, such as interim PET based risk stratification, would allow the selection of high risk patients for treatment intensification while at the same time sparing patients unnecessary toxicity in patients destined to do well with R-CHOP alone.
Early studies indicated that FDG-PET performed after 2-4 cycles of R-chemotherapy is predictive of outcome in patients with DLBCL [8] [9] [10] [11] [12] . More recent reports have called this into question, perhaps due to the diversity of imaging and interpretative methodologies that has led to wide variations in reported negative and positive predictive values for interim PET (iPET) scans [13] [14] [15] [16] [17] . One confounding factor is that iPET is typically performed after 2 cycles of R-chemotherapy when FDG-avidity likely reflects a mix of residual cancer cells and inflammation [18] [19] [20] . In contrast, iPET assessment after cycle 4 R-chemotherapy may more specifically identify resistant lymphoma 15, 21 and thereby enable more accurate identification 5 of high-risk patients on the basis of therapeutic response who may benefit most from early treatment intensification. Therefore, in this study we scheduled the iPET in the week following completion of cycle 4 R-CHOP (iPET-4), delaying cycle 5 by 7 days to reduce any confounding inflammatory effects within the tumour bed of immuno-chemotherapy.
Few studies in DLBCL have prospectively explored a change in treatment strategy guided by iPET responses [22] [23] [24] [25] . We chose to evaluate a change to HDT since it is the most widely accepted curative strategy for patients with DLBCL failing R-CHOP. We hypothesised that improved clinical outcomes for high risk DLBCL patients with poor prognosis as identified by iPET after 4 chemotherapy cycles would be achieved with early HDT and ASCT delivered when there is a lower burden of chemo-resistant disease than if instituted at the time of radiologic progression. Given favourable reports of the use of radio-immunotherapy combined with ASCT for patients with relapsed/refractory DLBCL, the study combined 90 Yibritumomab tiuxetan (Zevalin ® ) with high dose BEAM (Z-BEAM) chemotherapy [26] [27] [28] .
METHODS

Study Design
This prospective multi-centre phase II study enrolled patients aged 18 to 70 years, ECOG performance status (PS) 0-3, with high risk DLBCL (either IPI 2-5 or 0-1 with bulk >7.5 cm), previously untreated (excepting pre-phase prednisone), considered fit for ASCT, and with a positive baseline PET scan with >1 FDG-avid lesion.
All patients underwent a baseline PET prior to receiving 4 cycles of dose-dense R-CHOP- 
PET Imaging and Analysis
Patients were injected with 370 MBq of [ 
Post-iPET Treatment
Interim PET-negative patients completed 2 further cycles of R-CHOP-14 followed by 2 doses of 2-weekly Rituximab. Interim PET-positive patients received R-ICE chemotherapy (see supplemental text) every 21 days for 3 cycles. Peripheral blood stem cells were mobilised with filgrastim at 10 μ g/kg daily. Subsequently, patients without PD after 3 cycles of R-ICE proceeded to ASCT using Z-BEAM conditioning 2-6 weeks (typically 3) from day 1 of cycle 3 R-ICE; patients with PD were taken off study. At a central site ibritumomab tiuxetan was labelled to 90 Yttrium (see supplemental text) as part of the Z-BEAM regimen as previously published 26 .
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Statistical Methods
The primary endpoint was 2-year PFS for patients remaining iPET-positive and treated with R-ICE and Z-BEAM. PFS was defined as the time from the iPET scan to disease progression or death from any cause. The expected 2-year PFS rate for iPET-4-positive patients treated with R-CHOP based on historical data was considered to be 40% (range, 36-47%) 11, 12, 15, 17, 21 . By switching these patients to early treatment intensification the aim was to increase the 2-year PFS to 65%. A one-stage design with 33 iPET-positive patients provided a probability of at least 90% to detect a difference in 2-year PFS of 40% versus 65% with a two sided alpha of 0.05. Since it was expected that at least 20% would be iPET-positive, the planned accrual was 165. The major secondary endpoint was overall survival (OS). A subsequent exploratory analysis involved iPET assessment using the 5-PS by two blinded readers. Statistical analyses were performed using Stata MP vs 13.1 software (StataCorp, USA).
RESULTS
Patient Characteristics
Between July 2009 and December 2012, 162 patients were enrolled from 20 Australian centres. Subsequently, 11 patients were excluded for failure to meet the eligibility criteria.
Baseline characteristics of the 151 evaluable patients include: median age 57 (range, 21 to 69) years, 79% stage 3-4, 54% bulky disease, and 54% IPI 3-5 (Table 1) .
Interim PET Results
No iPET scan was performed in 8 patients due to PD (n=1), bowel perforation (n=2), organ toxicity (n=3), and dose delays including PR in 8 (25%) and SD in 2(6%), while 2 (6%) were not evaluated.
Treatment Outcomes
The principle aim of the study was achieved. On an intention to treat basis, at a median follow-up time of 35 months, the iPET-positive patients showed a 2-year PFS of 67% (95% CI, 50-79%), a rate similar to that seen among iPET-negative patients (74%) (95% CI, 64-81%) (P=0.32) (Figure 2A ). The 2-year OS was similar for iPET-positive and iPET-negative cohorts at 78% (95% CI, 60-88%) and 88% (95% CI, 79-93%) (P=0.11), respectively ( Figure 2B ). Among patients with high IPI 3-5, 2-year PFS and OS rates were comparable (supplemental figures 1A and 1B).
At least one grade 3-4 adverse event was reported in 58% of iPET-negative patients 
iPET Assessment Using the Deauville 5-Point Scale (5-PS)
In a post-hoc exploratory analysis iPET-positive scans were scored by two blinded readers with a visual interpretation using the Deauville 5-PS 15, [29] [30] [31] [32] , and survival outcomes were evaluated accordingly. Of the entire 42 iPET-positive patients, 27 were Deauville score 4 and 15 were score 5. There was a notable difference in 2-year PFS for Deauville score 4 versus score 5, at 88% (95% CI, 66-96%) versus 33% (95% CI, 12-57%) (P=0.0002), respectively ( Figure 3A) , and similarly for 2-year OS at 96% (95% CI, 74-99%) versus 42%
(95% CI, 15-67%) (P=0.001), ( Figure 3B ).
Univariate and Multivariate Analyses (MVA)
In univariate Cox proportional hazards model, status on iPET was not significant for either PFS (P=0.327) or OS (P=0.122), respectively. MVA factors significantly associated with PFS included B symptoms, stage 3-4 disease, and, with OS included age >60 years, ECOG PS >1, BM involvement, and iPET positive Deauville score 5 ( Table 2 ).
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DISCUSSION
We present the largest study published to date examining iPET-directed treatment intensification in DLBCL. Historically, the expected 2-year PFS rate for iPET-4-positive patients treated with R-CHOP is approximately 40% 11, 12, 15, 17, 21 . The aim of this study was to determine if patients with poor prognosis DLBCL who are iPET-positive after 4 cycles of R-CHOP-14 and receive treatment intensification with R-ICE followed by Z-BEAM ASCT, could obtain 2-year PFS of >65%. Not only was this achieved, but we show that this highrisk group of patients had survival outcomes similar to that for iPET-negative patients who receive standard R-CHOP. Furthermore, in an exploratory analysis of the Deauville 5-point scale to quantify the iPET scan, both PFS and OS were markedly superior in patients who are iPET-positive scoring 4 on the 5-PS compared to those scoring 5.
In combining Zevalin with BEAM we confirm the feasibility and efficacy of the intensified combination in this adverse risk patient group, particularly for those with Deauville score 4.
As expected, however, this approach is associated with greater toxicity, supporting restriction of its use to those patients with a high risk of treatment failure. Four patients displayed somewhat delayed platelet engraftment beyond day 30, as has been described previously 27, 28 . This study pre-dated the results of the randomised study in chemo-sensitive relapsed DLBCL comparing 131 iodine-tosituzumab-BEAM and Rituximab-BEAM (R-BEAM) regimens and which produced similar 2-year PFS and OS rates 33 . Accordingly, we cannot exclude the possibility that the results would have been the same had we used R-BEAM instead of Z-BEAM.
At the time of study design the issue of the optimal timing for iPET remained to be established 32, 34, 35 . Considerations include the need to deliver potentially curative therapy in a timely manner while avoiding treatment toxicity in patients with a favourable prognosis, as against the desire to delay iPET and improve specificity by reducing the extent of rebound 11 inflammation after the most recent immuno-chemotherapy cycle. Given the need to robustly identify poor responders, and given reports indicating 2-year PFS rates for iPET4-positive patients of approximately 40% 11, 12, 15, 17, 21 we chose to perform the iPET after 4
cycles of R-CHOP-14. Secondly, 2-versus 3-weekly R-CHOP has been shown in randomised controlled studies to have equivalent efficacy 3 . This suggests that our approach of delaying cycle 5 by 7 days to permit a centrally reviewed iPET scan performed at d17-d20 post-4th R-CHOP did not impact outcome while at the same time noting that a 7-day delay alone may not have necessarily improved the PPV.
Despite using IHP criteria in this study, none of the iPET scans initially rated as positive were subsequently assessed on the 5-PS as Deauville score 3 (uptake ≤ liver but > mediastinum). There is often heterogeneity of liver FDG activity as well as significant intersubject variability in patients with DLBCL, likely due to the reversible changes in the liver metabolism during immuno-chemotherapy, and often leading to variable agreement among PET readers 36 . In the present study, some iPET scans potentially considered Deauville score 3 may have been interpreted as score 2 for the purposes of IHP criteria, however, the 29% rate of iPET-positivity is highly consistent with that reported among high risk patients in other studies using the 5-PS 16, 29, 30 .
Some investigators have evaluated a quantitative PET approach, with reports suggesting that iPET analysis using ΔSUV max provides a higher PPV than qualitative analysis and therefore lower rates of PET-positivity 21, [37] [38] [39] [40] . However, these studies have predominantly assessed the ΔSUV max at iPET-2, as well as using somewhat variable cut-off values, with a lack of congruence between PET centres, and limited validation in multi-centre trials 21, [37] [38] [39] [40] .
At the iPET-4 time-point, ΔSUV max has been less commonly utilized 37 while some studies have suggested that visual assessments using the liver as background may be equivalent 12 to quantitative models at predicting PFS 21, 32 . Secondly, some recent studies have shown end of treatment PET to carry the highest PPV compared to iPET 16, 41, 42 . Consequently, early biopsy of FDG-avid sites has been recommended since, in one large prospective study, iPET-positive patients who were biopsy-negative displayed outcomes equivalent to that for iPET-negative patients, with the caveat that both patient groups were switched to R-ICE treatment intensification 43 . As in the vast majority of studies, however, we did not assess biopsies taken from iPET-positive residual masses. Undertaking biopsies during treatment can be problematic since the affected sites are often very difficult to access surgically or radiologically, with the associated risks of bleeding, infection, sampling error, inadequate tissue, and resultant treatment delays that may adversely affect outcomes.
The feasibility and efficacy of the use of salvage therapy and ASCT among iPET-positive DLBCL patients has been assessed in 3 smaller prospective studies [22] [23] [24] . Notably, these trials showed higher rates of iPET-positivity of 39%, 51%, and 71%, compared to 29% in the present study, meaning that more patients were subject to HDT, yet still displayed rates of 2-year PFS (66%, 57%, and 65%) that were no better than that seen in the current study (67%). Other notable differences with these 3 studies were that iPET scans were undertaken earlier in the treatment course (after 2 or 3 induction cycles), and, that the 5-PS was not utilised. In contrast, 3 prospective trials have evaluated treatment intensification with chemotherapy alone for iPET-positive patients and showed relatively inferior outcomes compared to the trials incorporating ASCT 25, 44, 45 . Importantly, and in contrast to our study, iPET-positive patients either failed to complete the salvage therapy (due primarily to toxicity) 26, 44 , and/or derived minimal benefit from the treatment intensification 45 , and hence displayed relatively unfavourable survival outcomes.
We cannot exclude the possibility that some iPET-positive patients may have converted to PET-negativity with additional cycles of standard R-CHOP treatment, and may have gone 13 on to be cured. As against this, there was a substantial difference in 2-yr PFS observed between iPET-positive Deauville score 4 (88%) and score 5 (33%) patients, as well as favourable comparisons for PFS in iPET-positive patients compared to the iPET-negative cohort and to historical controls. Only a randomised study comparing treatment intensification to continued R-CHOP in iPET-positive patients can definitively address this issue.
In summary, this study provides support for the further investigation of early selection of poor prognosis DLBCL patients, as identified by iPET scanning, who might benefit from alternative therapeutic approaches to improve outcomes. It lends weight to the role of treatment intensification for those patients who are iPET-positive Deauville score 4, and suggests that novel strategies need to be explored for those who are score 5. 
